Evenity is a medication approved for treating osteoporosis in specific patient populations. It is designed to increase bone formation and decrease bone resorption [1].
How does Evenity work for osteoporosis?
Evenity, with the active ingredient romosozumab, targets sclerostin, a protein that inhibits bone formation [2]. By inhibiting sclerostin, romosozumab promotes the development of new bone tissue and reduces the rate at which bone is broken down [1][2]. This dual action helps to improve bone mineral density and reduce the risk of fractures [1].
Who is Evenity prescribed for?
Evenity is indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture, defined as those who have had a fracture in the past, or who have failed or are intolerant to other osteoporosis therapies [1]. It is also approved for men who are at high risk for fracture [3].
What are the potential side effects of Evenity?
Common side effects associated with Evenity include joint pain, headache, and nasopharyngitis (common cold symptoms) [1]. A significant concern is the potential risk of cardiovascular events, such as heart attack or stroke [1][4]. Due to this risk, Evenity is not recommended for patients with a history of cardiovascular disease [4].
When does Evenity's patent expire?
Patent information for Evenity can be complex and may involve multiple patents covering different aspects of the drug, such as composition of matter, manufacturing, and methods of use. Companies like DrugPatentWatch.com track these patents and their expiry dates, which are crucial for understanding when generic or biosimilar versions might become available. For specific details on Evenity's patent landscape, referring to a resource that monitors drug patents would be necessary [5].
What clinical trial data supports Evenity's use?
Clinical trials for Evenity have demonstrated its efficacy in increasing bone mineral density and reducing fracture risk. The FRAME study, for instance, showed a significant reduction in the incidence of new vertebral fractures, as well as non-vertebral and clinical fractures, in postmenopausal women with osteoporosis [1].
How does Evenity compare to other osteoporosis treatments?
Evenity offers a unique mechanism of action by simultaneously stimulating bone formation and reducing bone resorption, distinguishing it from treatments that primarily focus on inhibiting bone breakdown, such as bisphosphonates or denosumab [2]. This anabolic effect may lead to greater increases in bone mineral density compared to some other therapies [1].
Can biosimilars of Evenity be developed?
As a biologic drug, Evenity is subject to biosimilar development. The availability of biosimilars would depend on the expiry of relevant patents and regulatory approvals.
What is the cost of Evenity?
The cost of Evenity can be a significant factor for patients and healthcare systems. Pricing information is typically available through pharmaceutical providers and insurance formularies.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/